Galera Therapeutics (GRTX)
OTHER OTC:GRTX
Want to see GRTX full AI Analyst Report?
GRTX Stock Chart & Stats
$0.02
<$0.01(0.99%)
At close: 4:00 PM EST
$0.02
<$0.01(0.99%)
Day’s Range― - ―
52-Week Range$0.02 - $0.15
Previous CloseN/A
Volume48.38K
Average Volume (3M)63.57K
Market Cap
$16.05M
Enterprise Value$1.21M
Total Cash (Recent Filing)$6.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)<0.1
Beta1.79
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding160,429,780
10 Day Avg. Volume87,114
30 Day Avg. Volume63,573
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.33
Price to Sales (P/S)0.00
P/FCF Ratio-0.36
Enterprise Value/Market Cap0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Merger & $350M FinancingThe Obsidian all‑stock merger plus an oversubscribed $350M private placement funds the combined company into 2H2028 and repositions Galera as a minority holder in an immuno‑oncology platform. This materially reduces near‑term financing risk and supports execution of OBX‑115 clinical readouts in 2027, enabling program continuity and strategic optionality through key development milestones.
Major Deleveraging And Equity RepairReported elimination of debt in 2025 and a move to small positive equity materially reduce leverage and near‑term solvency risk. The balance‑sheet repair improves financial flexibility, lowers default probability and strengthens negotiating power for partnerships or licensing, enhancing the company's resilience over the medium term despite modest capital levels.
Preferred Conversion Increases Capital FlexibilityThe Series B preferred conversion amendment gives management a practical tool to simplify the capital structure and act quickly on strategic financings or merger mechanics. That flexibility can reduce class‑conflict risk, streamline ownership ahead of transactions, and lower friction for future equity actions—supporting smoother execution of corporate restructurings or financings over the medium term.
Bears Say
No Product RevenueGalera is a pre‑revenue biotech with reported revenue of $0 from 2020–2025, so its business economics depend entirely on clinical outcomes, licensing or M&A. Without product cash flow, long‑term sustainability hinges on successful trials or partner deals, making the firm's fundamentals highly binary and reliant on external capital over the medium term.
Persistent Negative Cash GenerationOperating and free cash flows were materially negative from 2020–2024 and show $0 in 2025, indicating no durable internal cash generation. This structural cash burn forces reliance on external financing, increasing dilution and limiting strategic choices; even with recent financing, continued outflows tied to R&D elevate medium‑term funding risk.
Thin Asset Base And Prior Negative EquityThe company reports modest assets (~$7.2M) and only a small positive equity cushion (~$4.0M) in 2025 after years of negative equity. A thin tangible capital base limits downside absorption, weakens collateral for creditors, and amplifies the consequences of clinical or operational setbacks, increasing the probability of future dilution or restructurings if programs underperform.
Galera Therapeutics News
GRTX FAQ
What was Galera Therapeutics’s price range in the past 12 months?
Galera Therapeutics lowest stock price was $0.01 and its highest was $0.15 in the past 12 months.
What is Galera Therapeutics’s market cap?
Galera Therapeutics’s market cap is $16.05M.
When is Galera Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Galera Therapeutics’s earnings last quarter?
Currently, no data Available
Is Galera Therapeutics overvalued?
According to Wall Street analysts Galera Therapeutics’s price is currently Overvalued.
Does Galera Therapeutics pay dividends?
Galera Therapeutics does not currently pay dividends.
What is Galera Therapeutics’s EPS estimate?
Galera Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galera Therapeutics have?
Galera Therapeutics has 160,429,780 shares outstanding.
What happened to Galera Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Galera Therapeutics?
Currently, no hedge funds are holding shares in GRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galera Therapeutics
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
8.95% Insiders
<0.01% Mutual Funds
1.83% Other Institutional Investors
89.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---